Oshima Junya, Inoue Yoshiaki, Sasaki Kaoru, Sekido Mitsuru
Department of Plastic, Reconstructive, and Hand Surgery, University of Tsukuba, Tsukuba, JPN.
Department of Emergency and Critical Care Medicine, University of Tsukuba Hospital, Tsukuba, JPN.
Cureus. 2025 Apr 29;17(4):e83210. doi: 10.7759/cureus.83210. eCollection 2025 Apr.
RECELL® autologous cell harvesting device (AVITA Medical, Inc., Santa Clarita, California, United States) is a non-cultured autologous skin cell suspension (ASCS) device that rapidly processes a small sample of the patient's own skin into a cell suspension that can be sprayed onto large burn wounds. The ASCS system is considered to be effective for treating burns in children, especially because it minimizes new scars caused by skin harvesting; however, there are very few reports on ASCS monotherapy without autologous split-thickness skin grafting in patients under three years of age. This report describes three cases of deep dermal burn in patients under the age of three years treated with ASCS monotherapy. The cases highlight the advantages of ASCS monotherapy, including expedited healing, reduced burden of wound care, and minimized scarring from skin harvesting. In ASCS monotherapy, challenges remain, including the fragility of the engrafted cells, the small but unavoidable need for skin harvesting, postoperative scarring, and high treatment costs. This report highlights the need for ongoing accumulation of case studies to refine treatment protocols and emphasizes the importance of extended follow-up to evaluate long-term outcomes, including the impact of growth on scar formation.
瑞赛细胞采集装置（美国加利福尼亚州圣克拉丽塔市的AVITA医疗公司）是一种非培养的自体皮肤细胞悬液（ASCS）装置，它能迅速将患者自身一小片皮肤样本处理成可喷涂在大面积烧伤创面上的细胞悬液。ASCS系统被认为对治疗儿童烧伤有效，尤其是因为它能将取皮造成的新瘢痕减到最小；然而，关于三岁以下患者不进行自体中厚皮片移植的ASCS单一疗法的报道非常少。本报告描述了三例接受ASCS单一疗法治疗的三岁以下患者的深度真皮烧伤病例。这些病例突出了ASCS单一疗法的优势，包括加速愈合、减轻伤口护理负担以及将取皮造成的瘢痕减到最小。在ASCS单一疗法中，挑战依然存在，包括移植细胞的脆弱性、虽小但不可避免的取皮需求、术后瘢痕形成以及高昂的治疗成本。本报告强调需要持续积累病例研究以完善治疗方案，并强调延长随访以评估长期结果（包括生长对瘢痕形成的影响）的重要性。
